ClinicalTrials.gg
RecruitingNCT05647213Updated Mar 13, 2026

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

A Phase 1 interventional study of iPSC-CL in Univentricular Heart, Congenital Heart Disease and Heart Failure NYHA Class III, sponsored by HeartWorks, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by HeartWorks, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Univentricular Heart with a site in United States — 13 open to participants now, 16 under way, none of them phase 3. Univentricular Heart · United States.

Planned enrollment
9th of 32
50 · median 24
Started
2023
with 3 others
Phase 1
3 of 55
1 open now
Primary completion
2027-09
later than 7 of 15 live
Registered
43rd of 55
by date

Among the 55 studies in Univentricular Heart with a site in United States, this one is the 9th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2023, is one of 3 in phase 1, reaches primary completion later than 7 of the 15 other live ones, and was the 43rd registered.

Univentricular Heart

86 studies on the registry are indexed under Univentricular Heart; 22 are open to participants now.

Browse Univentricular Heart studies →

Open to participants now

13 of the 55 studies in Univentricular Heart with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Univentricular Heart studies recruiting now, 8 (38%) set no upper age limit and 13 (62%) stop at 75 or younger; 16 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Univentricular Heart with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the safety of lab-grown heart cells made from stem cells in subjects with congenital heart disease. The main questions it aims to answer are:

  • Is this product safe to deliver to humans
  • Is the conduct of this trial feasible

Participants will be asked to:

  • Agree to testing and monitoring before and after product administration
  • Receive investigational product
  • Agree to lifelong follow-up Researchers will compare subjects from the same pool to see if there is a difference between treated and untreated subjects.
03

Conditions studied

  • Univentricular Heart
  • Congenital Heart Disease
  • Heart Failure NYHA Class III
  • Heart Failure NYHA Class IV

Keywords

  • univentricular
  • heart disease
  • iPSC
  • induced pluripotent stem cell
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Individuals may be considered eligible for enrollment for Part I of this study (Skin Punch ) if in the best judgment of the Principal Investigator they will meet eligibility criteria outlined below at the time it is determined acceptable product is available for administration (approximately 9 months post skin punch biopsy). Inclusion and exclusion criteria apply to both the treatment and control arms of the study unless otherwise specified.

Inclusion criteria

Inclusion Criteria

Individuals who meet all the following criteria are eligible for enrollment as study participants:

  • Age 18 to 40 years old
  • Subject must be able to understand and provide .
  • Univentricular congenital heart disease.
  • End-stage systolic heart failure, defined as Class IV according to (NYHA) with abnormal visually estimated below 40%.
  • Prognosis of 1 to 1.5 years survival at time of skin biopsy.
  • The patient falls into one of the following categories:

    • Currently listed for heart transplantation at an accredited program in the US but has an expected waiting time for a suitable organ that is likely longer than anticipated life-expectancy.
    • Has been denied access to a heart transplantation at an accredited US institution.
    • Is currently on or planning to be on mechanical support as destination therapy.
  • All guideline directed therapy available to the subject has been maximized, for a minimum of 3 months prior to enrollment.
  • Adequate social support system that facilitates subject participation in all study required tests and procedures and supports the subject's ability to comply with long-term study requirements.

Exclusion criteria

Exclusion Criteria

Individuals who meet any of the following criteria are not eligible for enrollment as study participants:

  • No available autologous iPSC-CL as defined by the manufacturer's release criteria. (This applies to Part II of the study and applies to the treatment arm only.)
  • History of symptomatic episodes of cardiac arrythmia requiring cardiac defibrillation or escalation of medications.
  • Heart failure with preserved .
  • Heart failure due to co-morbid conditions (e.g., amyloidosis, valvular heart disease, anemia).
  • greater than 500 ms.
  • Stage III or higher chronic kidney disease.
  • History of liver cirrhosis.
  • History of coronary artery disease.
  • Uncontrolled diabetes mellitus.
  • Any history of cancer.
  • for use of amiodarone for up to 3 months (treatment arm only).
  • Contraindication for insertion of Insertable Cardiac Monitor.
  • Contraindication for placement of LifeVest cardioverter defibrillator.
  • Positive serology testing for , , or Syphilis.
  • Obesity with greater than 30.
  • Current alcohol or drug abuse precluding heart transplantation.
  • Active infection requiring ongoing treatment.
  • Contraindication to anesthesia.
  • Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality of the data obtained from the study.
  • Inability or unwillingness of a participant to give written or comply with study protocol.
  • History of non-compliance.
  • Inability to be accompanied around the clock for any part of the first 3 weeks post product administration.
  • Uncontrolled depression.
  • Denied heart transplant due to social determinants.
  • Current participation in another cardiac interventional clinical trial that could confound the results of this study.
  • Previous heart transplant.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treated

    Subjects in Treated arm will receive one dose of Investigational Product. Within this arm are three dose levels. Dose level selection will be determined by product availability subjects have available product and when they can be treated. Dose levels will escalate in order of treatment date.

    Biological: iPSC-CL

  • No intervention
    Control

    Subjects who enroll but do not receive Investigational Product will be placed in the control arm.

Interventions

  • BiologicaliPSC-CL

    Autologous IPSCL

06

What researchers measure

Primary outcomes

  1. Short term safety

    The primary safety endpoint is short term safety defined as the rate of new or worsening serious adverse events (SAE) from any System Organ Class (SOC) within 3 months of the iPSC-CL delivery as compared to the control arm.

    Time frame: 3 months

  2. Feasibility

    The primary feasibility endpoint is the percentage of individuals with collected skin cells that meet all iPSC-CL release criteria and the percentage of individuals that have cells delivered.

    Time frame: 12 months

Secondary outcomes

  1. Long term safety

    Long term safety measured as new or worsening serious adverse events for two years after iPSC-CL delivery as compared to the control arm.

    Time frame: 2 years

  2. Cardiac High Sensitivity Troponin T

    Change from baseline in Cardiac High Sensitivity Troponin T at 3 hours (±30 min) and 6 hours (±30 min) after iPSC-CL delivery and at 1 month post-surgery as compared to the control arm.

    Time frame: 1 month

  3. NT-pro-BNP

    Change from baseline in NT-pro-BNP levels at 1 and 3 months post iPSC-CL delivery as compared to the control arm.

    Time frame: 3 months

  4. Tumor marker levels

    Change from baseline in tumor marker levels (PSA (males only), CA 125, CEA, CA 19-9, alpha-fetoprotein (AFP), CA 195, Alpha Subunit HCG) 3 months and annually after iPSC-CL delivery as compared to the control arm.

    Time frame: Three months from date of treatment and every 12 months after treatment, assessed up to 15 years

  5. Panel Reactive Antibody (PRA) levels

    Change from baseline in Panel Reactive Antibody (PRA) levels at 3 and 12 months post-iPSC-CL delivery as compared to the control arm.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Sep 2027, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Dec 12, 2022
StartActual
Feb 3, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Feb 2029
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05647213
Lead sponsor
HeartWorks, Inc.
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Feb 3, 2023
Primary completion
Sep 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Mar 13, 2026

Study contacts

Adam Armstrong
Contact
adam@webuildhearts.org
1-(507) 577-1764
Timothy J Nelson, M.D., Ph.D.
study director · HeartWorks, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion